Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Gazprom launched the fourth line of the Amur Gas Processing Plant

8/29/24 GAZP

Rosinter Restaurants Holding reported for 6 months of 2024 by IFRS

8/29/24 ROST

INARCTICA reported for 6 months of 2024 by IFRS

8/29/24 AQUA

United Medical Group reported for 6 months of 2026

8/29/24 GEMC

RusHydro reported for 6 months of 2026 by IFRS

8/29/24 HYDR

UTair reported for 6 months of 2024 by IFRS

8/29/24 UTAR

NCSP reports for 6 months of 2024 by IFRS

8/29/24 NMTP

NLMK reported for 6 months of 2024 by IFRS

8/29/24 NLMK

Volgogradenergosbyt reported for 6 months of 2024 by IFRS

8/29/24 VGSB

Bashinformsvyaz reported for 6 months of 2024 by IFRS

8/29/24 BISVP